Based on the data from GY018 and RUBY, do you offer immunotherapy in addition to carboplatin/paclitaxel first line to all patients with advanced endometrial cancer who qualify or only to those whose tumors are MMR protein deficient?

This is a timely question that many of us are struggling with. There is a shared desire to improve clinical outcomes in patients with metastatic, advanced pMMR EC. As you know, both the NRG GY018 and RUBY regimens were NCCN compendium listed after publication and simultaneous presentation. Important...

The question was in patients "with advanced disease who qualify". Not sure what that means. The GOG study was clinical stage III (clinical disease) and stage IV as well as recurrent disease with genetic abnormalities. In review of the published article, I do not see the number of patients with prima...